 |
|
Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents
A Network Meta-analysis
Bruce M. Psaty, MD, PhD;
Thomas Lumley, PhD;
Curt D. Furberg, MD, PhD;
Gina Schellenbaum;
Marco Pahor, MD;
Michael H. Alderman, MD;
Noel S. Weiss, MD, DrPH
JAMA. 2003;289:2534-2544.
ABSTRACT
| |
Context Establishing relative benefit or harm from specific antihypertensive agents is limited by the complex array of studies that compare treatments. Network meta-analysis combines direct and indirect evidence to better define risk or benefit.
Objective To summarize the available clinical trial evidence concerning the safety and efficacy of various antihypertensive therapies used as first-line agents and evaluated in terms of major cardiovascular disease end points and all-cause mortality.
Data Sources and Study Selection We used previous meta-analyses, MEDLINE searches, and journal reviews from January 1995 through December 2002. We identified long-term randomized controlled trials that assessed major cardiovascular disease end points as an outcome. Eligible studies included both those with placebo-treated or untreated controls and those with actively treated controls.
Data Extraction Network meta-analysis was used to combine direct within-trial between-drug comparisons with indirect evidence from the other trials. The indirect comparisons, which preserve the within-trial randomized findings, were constructed from trials that had one treatment in common.
Data Synthesis Data were combined from 42 clinical trials that included 192 478 patients randomized to 7 major treatment strategies, including placebo. For all outcomes, low-dose diuretics were superior to placebo: coronary heart disease (CHD; RR, 0.79; 95% confidence interval [CI], 0.69-0.92); congestive heart failure (CHF; RR, 0.51; 95% CI, 0.42-0.62); stroke (RR, 0.71; 0.63-0.81); cardiovascular disease events (RR, 0.76; 95% CI, 0.69-0.83); cardiovascular disease mortality (RR, 0.81; 95% CI, 0.73-0.92); and total mortality (RR, 0.90; 95% CI, 0.84-0.96). None of the first-line treatment strategies– -blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs),  -blockers, and angiotensin receptor blockers–was significantly better than low-dose diuretics for any outcome. Compared with CCBs, low-dose diuretics were associated with reduced risks of cardiovascular disease events (RR, 0.94; 95% CI, 0.89-1.00) and CHF (RR, 0.74; 95% CI, 0.67-0.81). Compared with ACE inhibitors, low-dose diuretics were associated with reduced risks of CHF (RR, 0.88; 95% CI, 0.80-0.96), cardiovascular disease events (RR, 0.94; 95% CI, 0.89-1.00), and stroke (RR, 0.86; 0.77-0.97). Compared with -blockers, low-dose diuretics were associated with a reduced risk of cardiovascular disease events (RR, 0.89; 95% CI, 0.80-0.98). Compared with -blockers, low-dose diuretics were associated with reduced risks of CHF (RR, 0.51; 95% CI, 0.43-0.60) and cardiovascular disease events (RR, 0.84; 95% CI, 0.75-0.93). Blood pressure changes were similar between comparison treatments.
Conclusions Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality. Clinical practice and treatment guidelines should reflect this evidence, and future trials should use low-dose diuretics as the standard for clinically useful comparisons.
INTRODUCTION
In 1993 and again in 1997, the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure recommended low-dose diuretics and -blockers as first-line treatment for patients with uncomplicated hypertension.1-2 This recommendation reflected the wealth of clinical trial evidence about the health benefits associated with low-dose diuretics and -blockers.3-8 The early trials of diuretics and -blockers had generally randomized patients with high blood pressure to active therapy or to placebo. Early answers were clearest for patients with the highest level of blood pressure.4-5 These studies answered the question of whether several specific antihypertensive treatments improved health outcomes.
Clear evidence of health benefits associated with diuretics and -blockers precluded further long-term placebo-controlled trials. Thus, the recent large long-term trials have evaluated one active treatment against another active treatment in terms of their ability to prevent cardiovascular events.9-15 In these active-treatment comparison trials, participants in each treatment group have been randomized to receive one of a variety of first-line agents, including not only diuretics and -blockers, but also -blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). These comparative trials address the question of which first-line treatment regimen is optimal.
As this history suggests, the clinical trials in hypertension have provided a patchwork of evidence about the health benefits of antihypertensive agents. Some trials used placebo or untreated controls, and others used active-treatment comparison groups. Among the latter, the choice of the treatment and comparison therapies has varied from one trial to the next. Several approaches to the synthesis of these complex data are possible.3, 16-17 The Blood Pressure Trialists, for instance, conducted a prospective series of mini–meta-analyses, but this method left many "unresolved issues"17(p1963) due to multiple comparisons and low power.18 In this study, we used a new technique, called network meta-analysis,19 to synthesize the available evidence from placebo-controlled and comparative trials in a single meta-analysis. In addition to updating our previous meta-analysis of low-dose diuretics,3 the primary aim was to compare low-dose diuretics with each of the other 5 active first-line therapies evaluated in large long-term trials in terms of major health outcomes.
METHODS
Using MEDLINE searches, previous meta-analyses,3, 16-17,20-24 and journal reviews from January 1995 through December 2002, we identified studies designed to evaluate the effects of antihypertensive therapies on the occurrence of myocardial infarction and stroke. For randomized trials, a MEDLINE search was used to identify randomized clinical trials designed to evaluate the effects of antihypertensive therapies on the occurrence of cardiovascular morbidity and mortality. To update the literature search conducted for a previous meta-analysis,3 the search strategy for 1995 to 2002 was based on the search terms cerebrovascular disorders or cerebrovascular disorder or heart diseases or heart disease and antihypertensive agents (therapeutic use) or hypertension (drug therapy). All available English and non-English abstracts were reviewed (n = 1097), and the full text was consulted as necessary to clarify eligibility status. We limited attention to the 6 most commonly used antihypertensive classes (diuretics, -blockers, CCBs, ACE inhibitors, ARBs, and -blockers).
To be eligible for inclusion, studies had to be randomized controlled trials that evaluated major cardiovascular disease end points in hypertensive patients over the course of at least 1 year. Trials that recruited patients who had congestive heart failure (CHF) or who had a myocardial infarction were not eligible. The treatment had to be unconfounded by other therapies, such as smoking cessation or lipid-lowering, but factorial design trials such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)12, 15 were eligible. Trials published since 1995 had to have a minimum of 400 person-years of observation. Open randomized trials that used an untreated control group were included,25-26 but we excluded nonrandomized studies,27 nonfactorial multiple risk factor intervention trials,28-29 trials using first-line agents other than the 6 noted above,30-31 and trials that used a placebo group plus other antihypertensive therapies to reduce blood pressure to the same target level as the active treatment.32-34
All eligible trials4-15,25-26,35-71 are listed in Table 1 with data on number of events by randomized group. Data for one trial69 were finalized after the search was completed.68 Data were abstracted independently by 2 of the authors (B.M.P. and G.S.), and differences were resolved by consensus.
|
|
|
|
Table 1. Cardiovascular Events and Outcomes by Randomized Treatment
|
|
|
Coronary heart disease (CHD) included fatal and nonfatal myocardial infarction and CHD death; stroke, fatal and nonfatal stroke; and CHF, fatal and nonfatal CHF. Cardiovascular disease events included CHD, stroke, CHF, and other cardiovascular disease mortality. While the definition of end points varied slightly among the trials, the end point definitions and methods of classification were identical across treatment groups within each trial. For all comparisons, this meta-analysis aggregates these in-trial comparisons across studies.
Each arm of the trials was classified according to its primary treatment strategy. While most studies used more than 1 drug in a treated group, the agents were usually applied in a stepped-care approach so that the first-line therapy was clearly identified. The primary treatment strategies of interest in this meta-analysis were (1) placebo, untreated, or usual care; (2) low-dose diuretic therapy, which generally started with the equivalent of 12.5 to 25 mg per day of chlorthalidone or hydrochlorothiazide; (3) -blocker therapy; (4) ACE inhibitors; (5) ARBs; (6) CCBs; and (7) -blockers. High-dose diuretic therapy was defined as starting doses greater than or equal to the equivalent of 50 mg of chlorthalidone or hydrochlorothiazide and titrating upward72; diuretic dosages were unstated in 2 studies,25, 35 but were assigned to the high-dose diuretic group. While high-dose diuretics were included in the standard meta-analysis73 that compared any therapy with no therapy, this treatment strategy is not presented as part of the network meta-analysis since high-dose diuretic therapy is no longer used or recommended for the treatment of high blood pressure. None of the CCBs was a short-acting drug or formulation.
For the main analysis, the logarithm of the relative risk (RR) for each trial and its SE were calculated and used in a network meta-analysis.19 Network meta-analysis preserves the within-trial randomized comparison of each study and, at the same time, combines all available comparisons between treatments. These comparisons included both the direct within-trial comparisons between 2 treatment strategies and the indirect comparisons constructed from 2 trials that have 1 treatment in common. By way of illustration, the Intervention as a Goal in Hypertension Treatment (INSIGHT)9 trial provided a direct within-trial comparison of diuretics and CCBs for stroke (RR of 1.11 in favor of CCBs) and for CHF (RR of 0.46 in favor of diuretics). Systolic Hypertension in the Elderly Program (SHEP)45 and Systolic Hypertension in Europe Trial (SYST-EUR),53 both placebo-controlled trials, used diuretics and CCBs as active treatment. Therefore, the RRs from these 2 placebo-controlled trials can be used to provide estimates of the RR for the indirect comparison between diuretic and CCBs. For the outcome of stroke, multiplying the RR for diuretics vs placebo in SHEP times the RR for placebo vs CCBs in SYST-EUR yielded an indirect comparison of 0.65 x 1.69 = 1.10 in favor of the CCB, which was almost identical to the direct estimate of 1.11 from INSIGHT. For the outcome of CHF, the indirect comparison produced an RR of 0.70 (in favor of diuretics; from 0.53 x 1.33) compared with the direct estimate of 0.46 from INSIGHT. Other indirect comparisons can be computed with 2 or more intermediate treatments rather than the placebo-treatment arm used in this example. Network meta-analysis combines all available direct and indirect comparisons.
As Bucher et al74 have shown, indirect estimates can be combined in large samples if there is no interaction between the treatment effects and the populations or major subgroups in a trial. This requirement for combining similar effect estimates across trials also holds for standard meta-analyses. Indirect estimates cannot simply be assumed to be reliable. The reliability of treatment effects is assessed by computing the differences between various comparisons of the same 2 treatments. The variance of these differences over and above what would be expected from sampling error within each trial is expressed as a variance estimate called the "incoherence" of the network of trials. In the example used in the previous paragraph, the direct and indirect RRs for CHF (0.46 vs 0.71) were more incoherent or heterogeneous than the direct and indirect RRs for stroke (1.11 vs 1.10). Incoherence is a property of the fitted model, and it is incorporated in inferences in a similar way to the heterogeneity estimate in a standard random-effects meta-analysis.73 When the incoherence is small or moderate, it is used to increase the SE of the estimated treatment differences and to reduce the weight given to indirect comparisons. When the incoherence is sufficiently large, combining the trials may not be appropriate.
These computations were performed by fitting a linear mixed model to the log RRs from each trial with a random effect specific to each pair of treatments. Weights were used to avoid double counting of trials, such as ALLHAT,15 that had 3 or more arms. The single line of R source code required to estimate each model appears in Figure 4 of the network meta-analysis methods article by Lumley.19 Each of the 6 main analyses modeled a single outcome as a function of the various first-line treatment strategies. A similar random-effects linear mixed model was used to evaluate blood pressure differences between treatments, and the inverse of the sample size was used for the weights. Because the estimated incoherence for each meta-analysis was small, the incoherence had only a small effect on the width of the confidence intervals (CIs).
Our primary hypothesis involved low-dose diuretics, which are currently recommended as the first-line therapy.1 The RRs that are less than 1.0 indicate that low-dose diuretic therapy is superior to the comparison treatment strategy. We evaluated 2 alternative approaches to handling trials that included both diuretics and -blockers in a single treatment group.10, 13-14,47 In one approach, the 2-drug category was included as a separate treatment, and in the other, the trials were weighted according to the allocation of 68% to -blockers and 32% to diuretics.75 Since the 2 approaches yielded almost identical estimates of the associations for placebo and -blockers, we decided to present the simpler model in this article. We also evaluated alternative models that included separate categories for the dihydropyridine CCBs and the nondihydropyridine CCBs. With RRs of less than 1.0 indicating that nondihydropyridines were superior to dihydropyridines, the RRs were 1.12 (95% CI, 0.86-1.46) for CHD; 0.96 (95% CI, 0.76-1.21) for stroke; 0.96 (95% CI, 0.75-1.21) for heart failure; 0.94 (95% CI, 0.81-1.09) for cardiovascular disease events; 0.87 (95% CI, 0.71-1.06) for cardiovascular disease mortality; and 0.93 (95% CI, 0.74-1.09) for total mortality. Since there were no significant differences between the 2 subclasses, the CCBs were presented as a single treatment strategy.
RESULTS
The 42 trials from the United States, Europe, Scandinavia, Australia, Japan, and China included a total of 192 478 patients followed up for an average of 3 to 4 years. The high-dose diuretic trials, generally completed in the 1970s and 1980s, were followed by trials that used low-dose diuretics. Trials completed in the last decade were usually larger than the early trials, and some of them recruited special populations, including individuals with diabetes,56, 58, 60, 66-67 older adults,41-42,45, 53 those with a history of cerebrovascular disease,25, 50, 65 and blacks with renal disease.62-63 Some details about individual trials are provided in Table 1 and in previous meta-analyses.3, 16-17,20-24 ALLHAT,15 which has not been part of a previous meta-analysis, included 33 357 participants aged 55 years or older with at least 1 other CHD risk factor (mean follow-up was 4.9 years).
The standard meta-analysis of any drug treatment vs no treatment, which omits all active-control trials, appears in Table 2. Compared with placebo, an untreated control group, or usual care, any active treatment was associated with important reductions in the risk of all major outcomes. Combining all types of active treatments in this analysis involved the unevaluated assumption that all treatments had a similar effect. For the outcomes of stroke and major cardiovascular events, there was significant heterogeneity, which may be the result of important differences between drug classes.
|
|
|
|
Table 2. Fixed and Random Effects Meta-analysis Comparing any Antihypertensive Drug Treatment vs No Treatment for Each Outcome*
|
|
|
For the network meta-analysis, we first conducted an analysis that excluded ALLHAT,15 the largest comparative trial and the mixed -blocker diuretic trials.10, 13-14,47, 70 Table 3 summarizes 3 independent sets of RRs that compare low-dose diuretics with CCBs or ACE inhibitors: the ALLHAT results; the direct comparisons between trials9, 52, 55, 61, 69 other than ALLHAT; and indirect comparisons between the trials other than ALLHAT. For the comparison between diuretic and ACE inhibitor, the 1 remaining direct comparison trial was the Second Australian National Blood Pressure study.69 Depending on the outcome, the indirect comparisons used information from 14 to 24 trials or pairs of trial arms (Figure 1); and the indirect comparisons included paths that passed through placebo, low-dose diuretics, -blockers, and CCBs. For 5 of the 6 outcomes, the point estimates for the indirect meta-analysis of diuretics and ACE inhibitors were closer to those of ALLHAT than the direct estimates from the Second Australian National Blood Pressure Study. For all outcomes and for both drug comparisons, the point estimates from the 3 sources of data were generally similar. Neither the direct nor the indirect estimates differed from ALLHAT in a systematic way across outcomes. The similarity among estimates suggests that combining data from the 3 sources is reasonable and appropriate.
|
|
|
|
Table 3. ALLHAT vs Meta-analysis* of the Other Direct and Indirect Evidence Comparisons of Calcium Channel Blockers and Angiotensin-Converting Enzyme Inhibitors With Low-Dose Diuretics
|
|
|
|
|
|
|
Figure 1. Network Meta-analysis of First-Line Antihypertensive Drug Treatments
Each first-line drug treatment is a node in the network. The links between the nodes are trials or pairs of trial arms. The numbers along the link lines indicate the number of trials or pairs of trial arms for that link in the network. Reference numbers indicate the trials contributing to each link. A trial such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial12, 15 (ALLHAT) with multiple arms appears along several links (diuretics-angiotensin-converting enzyme (ACE) inhibitors, diuretics-calcium channel blockers (CCBs), ACE inhibitors-CCBs, and diuretics--blockers). High-dose diuretic trials were excluded.
|
|
|
Figure 2 was constructed from the network meta-analyses to highlight treatment comparisons for all major end points. In Figure 2A, low-dose diuretic therapy was compared with placebo. The RRs were significantly less than 1.0 for all 6 outcomes: CHD (RR, 0.79; 95% CI, 0.69-0.92); CHF (RR, 0.51; 95% CI, 0.42-0.62); stroke (RR, 0.71; 0.63 -0.81); cardiovascular disease events (RR, 0.76; 95% CI, 0.69-0.83); cardiovascular disease mortality (RR, 0.81; 95% CI, 0.73-0.92); and total mortality (RR, 0.90; 95% CI, 0.84-0.96).
|
|
|
|
Figure 2. Network Meta-analysis of First-Line Treatment Strategies in Randomized Controlled Clinical Trials in Hypertension
Asterisks, placed after the closed parentheses of the 95% CI, indicate that -blockers (P<.05), angiotensin-converting enzyme inhibitors (P<.05), calcium channel blockers (P<.05), and angiotensin-receptor blockers (P<.05) were significantly better than placebo for that outcome. -Blockers were not significantly better than placebo for any outcome (P>.05). CHD indicates coronary heart disease; CHF, congestive heart failure; CI, confidence interval; CVD, cardiovascular disease; and RR, relative risk.
|
|
|
Figure 2B compares the performance of -blockers with low-dose diuretics. For all outcomes, low-dose diuretics were associated with a lower point estimate for events than -blockers, but the findings were significant only for the incidence of cardiovascular disease events (RR, 0.89; 95% CI, 0.80-0.98). For some outcomes, (marked by asterisks), -blockers were significantly better than placebo. For cardiovascular disease events, specifically, the RR was 0.85 (95% CI, 0.78-0.94). The product (0.76) of these 2 RRs (0.85 x 0.89) represents the RR for low-dose diuretics vs placebo (Figure 2A).
In Figure 2C, low-dose diuretics were associated with a significantly lower risk of CHF (RR, 0.88; 95% CI, 0.80-0.96), stroke (RR, 0.86; 95% CI, 0.77-0.97), and cardiovascular disease events (RR, 0.94; 95% CI, 0.89-1.00) than ACE inhibitors. In Figure 2D, low-dose diuretics were associated with significantly lower risks of CHF (RR, 0.74; 95% CI, 0.67-0.81) and cardiovascular disease events (RR, 0.94; 95% CI, 0.89-1.00) than CCBs. For the other outcomes in Figure 2C and Figure 2D, the differences did not achieve conventional levels of significance (P<.05). Again, asterisks in these figures indicate that the drug class differs significantly from placebo for that outcome.
Only 3 trials evaluated ARBs, and in Figure 2E, all the CIs for RRs comparing ARBs and low-dose diuretics included the null. The comparison of -blockers and low-dose diuretics (Figure 2F) was based on data from ALLHAT.12
The estimates of incoherence for each outcome in this network meta-analysis were small (Table 4). For instance, the differences between the direct and the indirect comparisons of drugs in this meta-analysis inflated the width of the 95% CI by about 0.5% for CHD and by about 5% for cardiovascular disease mortality. While low-dose diuretics were often associated with slightly lower mean levels of blood pressure than other classes of antihypertensive drugs (Table 5), none of the differences was significant.
|
|
|
|
Table 4. Estimates of Incoherence
|
|
|
|
|
|
|
Table 5. Change in Systolic and Diastolic Blood Pressures for Each Drug Class Compared With Low-Dose Diuretics*
|
|
|
COMMENT
In this network meta-analysis, we combined clinical trial data from 42 studies that included 192 478 patients randomized to 7 major treatment strategies. For all outcomes, the network meta-analysis confirmed that low-dose diuretics were superior to placebo. While several other treatment strategies were significantly better than placebo for some end points, none of the other first-line treatment strategies–-blockers, ACE inhibitors, CCBs, -blockers, and ARBs–was significantly better than low-dose diuretics for any major cardiovascular disease outcome. In 8 of the 30 between-drug comparisons, however, low-dose diuretics were significantly better than other treatments for the prevention of cardiovascular disease health outcomes. Among nonsignificant between-drug comparisons, 13 favored low-dose diuretics, 5 favored other therapies, and 4 were indifferent. This network meta-analysis provides compelling evidence that low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality.
-blockers have long been identified as another preferred first-line treatment for hypertension. In this network meta-analysis, similar to our previous article,3 -blockers were superior to placebo for the prevention of stroke, CHF, cardiovascular disease events, and total mortality. At the same time, -blockers were inferior to low-dose diuretics for all outcomes, significantly so for cardiovascular disease events. For uncomplicated hypertension, -blockers should be considered a second-line antihypertensive agent.
There are no large long-term trials evaluating the optimal second-line antihypertensive therapy, which could include ACE inhibitors, CCBs, and ARBs, as well as -blockers. In addition to information about the health outcomes in hypertension trials, many investigators use the findings about major cardiovascular benefits from other large long-terms trials to recommend the use of specific drugs for compelling indications.1, 76 -blockers have been particularly effective in patients with coronary disease77-79 or heart failure,80-81 and many guidelines recommend them over CCBs as first-line therapy for improving health outcomes in secondary-prevention settings.82-86 Like -blockers, ACE inhibitors have also proven to be a robust therapy, effective in a number of secondary-prevention settings, including coronary disease87-88 and heart failure.89 ACE inhibitors, which may be preferred in special populations such as those with diabetes,90 are also superior to amlodipine in blacks with renal disease.62
Based exclusively on indirect comparisons, there were no significant differences between low-dose diuretics and ARBs. However, the number of ARB trials was small, and this analysis lacked power. The uncertainty occasioned by the small number of ARB trials is reflected in the wide CIs in Figure 2E.
In this meta-analysis (Table 5) and in several of the comparative trials, including ALLHAT,15 the various treatment strategies were associated with slightly different amounts of blood-pressure lowering. The RRs estimated for the outcomes in this meta-analysis preserved the within-trial comparisons of the treatment strategies just as they were implemented and without adjustment for any in-trial blood pressure differences that may have occurred. In ALLHAT,15 adjustment for in-trial blood pressure had minor effects on the estimated RRs. While differences in outcomes in this network meta-analysis may reflect differences in achieved levels of blood pressure, the blood pressure differences were generally small (Table 5). Epidemiological evidence from the Framingham Heart Study91 suggests that adjustment for the 2.4-mm Hg difference in systolic blood pressure between low-dose diuretics and CCBs (Table 5) would have increased the RR for heart failure in Figure 2D only slightly–from 0.74 to about 0.77.
Previous traditional meta-analyses have been constrained by the evolving configuration of the trial designs. With standard techniques of meta-analysis, comparisons of diuretics or -blockers with placebo were possible.3 Comparisons of CCBs to all other active therapies were also possible.16 Alternatively, it was possible to use various subsets of the trials to evaluate each major type of within-trial comparisons as the Blood Pressure Lowering Treatment Trialists did in their prospective series of mini–meta-analyses.17 All these traditional approaches to meta-analysis ignore part of the available data.
Network meta-analysis incorporates both the direct and indirect comparisons between treatments. In this study, the direct and indirect comparisons were similar (Table 3). Recent empirical evidence suggests the validity of indirect comparisons for a number of conditions and interventions.92 In a series of 44 meta-analyses that permitted comparisons between direct and indirect results, the number of significant differences (n = 3) was only slightly higher than the number expected by chance alone (n = 2.2). Song et al92 conclude that the validity of indirect comparisons depends on the internal validity and the similarity of the evaluated trials, including similarity in dose.
Like heterogeneity in traditional random-effects models of meta-analysis, incoherence is used to quantify variation among estimates and is incorporated into the estimation of the CI. Although the estimated incoherence of the final models in this network meta-analysis was low (Table 4), additional methodological and empirical work needs to be done to evaluate the direct and indirect comparisons across a number of types of interventions. Traditional limitations of meta-analyses due to variations in the treatment regimens, in populations or major subgroups within trials, and in the conduct of the trials also apply to this network meta-analysis.
As investigators gain experience with the use of indirect comparisons74, 92 and with the technique of network meta-analysis,19 it may be possible to forego some placebo-controlled trials in selected therapeutic areas. In the presence of compelling evidence of the effect of one drug against placebo, comparative trials with a second agent can provide indirect estimates of its effect against placebo.74, 92 This principle is the same as the requirement for good anchoring trials before launching equivalence trials.93-94
While an occasional hypertensive patient cannot take diuretics because of an allergy or an intolerable adverse effect,95 low-dose diuretics were significantly better than other therapies in reducing the occurrence of cardiovascular disease health outcomes for 8 of the 30 between-drug comparisons. In this network meta-analysis, the most effective drug was also the least expensive. Thus, cost-effectiveness analyses are not required.
Based on extensive clinical trial evidence, meta-analysis, and network meta-analysis, low-dose diuretics are the treatment of first choice for patients with uncomplicated hypertension who need pharmacological therapy. Moreover, low-dose diuretics should serve as the active-treatment control arm of future superiority or equivalence trials in patients with hypertension. Trials evaluating the optimal second-line treatment strategy may be appropriate. Until then, recommendations about the best second-line therapies should be based, when possible, on evidence from large long-term outcome trials mounted for other compelling indications such as coronary disease and heart failure.76
AUTHOR INFORMATION
| |
Corresponding Author and Reprints: Bruce M. Psaty, MD, PhD, Cardiovascular Health Research Unit, Suite 1360, 1730 Minor Ave, Seattle, WA 98101 (e-mail: psaty{at}u.washington.edu).
Author Contributions: Study concept and design: Psaty, Lumley, Furberg, Schlellenbaum, Pahor, Weiss.
Acquisition of data: Psaty, Furberg, Schlellenbaum.
Analysis and interpretation of data: Psaty, Lumley, Furberg, Alderman, Weiss.
Drafting of the manuscript: Psaty, Alderman.
Critical revision of the manuscript for important intellectual content: Psaty, Lumley, Furberg, Schlellenbaum, Pahor, Alderman, Weiss.
Statistical expertise: Psaty, Lumley.
Obtained funding: Psaty.
Administrative, technical, or material support: Furberg.
Study supervision: Psaty.
Financial Disclosures: Dr Furberg is a lecturer for Merck-Frocst (Canada) and Merck. Dr Pahor has received research grants from Pfizer and Bristol-Myers Squibb and honoraria from Bristol-Myers Squibb. Dr Alderman has received research support from Merck and Pfizer and honoraria for speaking from Merck, Novartis, and Bristol-Myers Squibb.
Funding/Support: The research reported in this article was supported by grants HL40628, HL43201, and HL68639 from the National Heart, Lung, and Blood Institute; AG09556 from the National Institute on Aging; 9970178N from the Patient Care and Outcomes Research Program of the American Heart Association (AHA); and 0270054N from the AHA Pharmaceutical Roundtable Outcomes Research Program. Dr Psaty was a Merck/SER Clinical Epidemiology Fellow (sponsored by the Merck Co Foundation and the Society for Epidemiologic Research).
Author Affiliations: Departments of Medicine (Dr Psaty), Epidemiology (Drs Psaty and Weiss and Ms Schellenbaum), Health Services (Drs Psaty), and Biostatistics (Dr Lumley), Cardiovascular Health Research Unit, University of Washington, Seattle; Departments of Public Health Sciences (Dr Furberg) and Medicine (Dr Pahor), Wake Forest University Health Sciences, Winston-Salem, NC; and Department of Epidemiology and Social Medicine (Dr Alderman), Albert Einstein College of Medicine, Bronx, NY.
REFERENCES
1. Detection, Evaluation and Treatment of High Blood Pressure, Joint National Committee on Prevention. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
FULL TEXT
|
ISI
| PUBMED
2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
FULL TEXT
|
ISI
| PUBMED
3. Psaty BM, Smith NS, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277:739-745.
ABSTRACT
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:116-122.
FULL TEXT
| PUBMED
5. Veterans Administration Cooperative Study Group on Antihypertensive Agents II. Effects of treatment: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
FULL TEXT
| PUBMED
6. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97-104.
ISI
| PUBMED
7. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mild hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982;307:976-980.
ABSTRACT
8. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, III: reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633-638.
ABSTRACT
9. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
FULL TEXT
|
ISI
| PUBMED
10. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
FULL TEXT
|
ISI
| PUBMED
11. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
FULL TEXT
|
ISI
| PUBMED
12. ALLHAT Officers and Coordinator for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
FREE FULL TEXT
13. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
FULL TEXT
|
ISI
| PUBMED
14. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
FULL TEXT
|
ISI
| PUBMED
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
FREE FULL TEXT
16. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-l |
